Home » Topics » Drugs » Immuno-oncology

Immuno-oncology
RSS

Therion Biologics and the NCI move CEA-TRICOM cancer vaccine to phase I

Feb. 22, 2001

Phase II trials of SMART 1D10 antibody begin in non-Hodgkin's lymphoma

Feb. 21, 2001

Virulizin granted orphan drug status by FDA

Feb. 20, 2001

Distribution agreement for Pacis BCG terminated by UroCor and BioChem Pharma

Feb. 20, 2001

Melacine now available in Canada for treatment of stage IV melanoma

Feb. 16, 2001

Patient enrollment complete in phase IIb trial of IL-2 gene medicine for H&N cancer

Feb. 16, 2001

First-line therapy with rituximab in follicular lymphoma with low tumor burden

Feb. 13, 2001

Cancer vaccine designed at Progenics induces antitumor immune response in clinical trial

Feb. 13, 2001

ARGENT technology demonstrates potential in prostate cancer

Feb. 12, 2001

Antisoma's TheraFab enters phase I lung cancer trial

Jan. 29, 2001

Popular Stories

Today's news in brief
BioWorld
BioWorld briefs for June 22, 2026.
Alicorn synthesizes new AAK1 inhibitors
BioWorld Science
Researchers from Alicorn Pharmaceutical Co. Ltd. and Jiangsu Alicorn Pharmaceutical Co. Ltd. have disclosed crystalline salts of compounds acting as...
CFTX-2034 successfully shows promise for post-bariatric hypoglycemia in preclinical research
BioWorld Science
Researchers from Confo Therapeutics NV presented the preclinical characterization of CFTX-2034, a selective somatostatin receptor subtype 5 (SSTR5) agonist...
Saniona reports preclinical data for SAN-2668
BioWorld Science
Saniona AB has presented preclinical data and its clinical development strategy for its lead clinical candidate, SAN-2668, which is a GABA-A receptor positive...
Insilico Medicine synthesizes new Nav1.8 blockers
BioWorld Science
Insilico Medicine Inc. has identified sodium channel protein type 10 subunit α (SCN10A; Nav1.8) blockers that are potentially useful for the treatment of pain.